KRMD trades 94.2% below Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes KRMD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, KORU Medical Systems, Inc. (KRMD) has a Wall Street consensus price target of $6.00, based on estimates from 5 covering analysts. With the stock currently trading at $3.09, this represents a potential upside of +94.2%. The company has a market capitalization of $142M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KRMD trades at a trailing P/E of -84.2x. Analysts expect EPS to grow -6.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ATRCAtriCure, Inc. | $3.0B | $58.54 | $60.17 | +2.8% | Buy | 541.5x | 20 |
 INFUInfuSystem Holdings, Inc. | $276M | $13.69 | $15.00 | +9.6% | Buy | 29.8x | 4 |
 LMATLeMaitre Vascular, Inc. | $1.8B | $80.89 | $97.00 | +19.9% | Buy | 28.5x | 20 |
 BDXBecton, Dickinson and Company | $58.4B | $211.88 | $200.57 | -5.3% | Buy | 16.7x | 34 |
 BAXBaxter International Inc. | $13.3B | $25.79 | $23.83 | -7.6% | Hold | 12.3x | 36 |
 ICUSeaStar Medical Holding Corporation | $8M | $1.88 | $8.00 | +325.5% | Buy | — | 1 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.23 | $107.33 | +23.0% | Buy | 20.0x | 15 |
 NXRTNexPoint Residential Trust, Inc. | $413M | $16.26 | $20.50 | +26.1% | Hold | — | 11 |
 TNDMTandem Diabetes Care, Inc. | $1.2B | $16.91 | $23.19 | +37.1% | Buy | — | 39 |
 ITGRInteger Holdings Corporation | $4.3B | $126.56 | $118.25 | -6.6% | Buy | 20.8x | 16 |
Quick answers to the most common questions about buying KRMD stock.
The consensus Wall Street price target for KRMD is $6, representing 94.2% upside from the current price of $3.09. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
KRMD has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $6 implies 94.2% upside from current levels.
KRMD's current price is $3.09 with a consensus target of $6 (94.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for KRMD, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
KRMD is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month KRMD stock forecast based on 5 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on KRMD, with a "Buy" consensus rating and $6 price target (94.2% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
KRMD analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.